<DOC>
	<DOCNO>NCT01603264</DOCNO>
	<brief_summary>In study , healthy male volunteer receive single intravenous administration either PF-05280014 trastuzumab ( United States ) trastuzumab ( European Union ) . During course study , pharmacokinetics assess sampling level drug blood , compare level among different administration arm PF-05280014 US-licensed EU-approved trastuzumab product . Safety , tolerability , immunologic response also evaluate throughout .</brief_summary>
	<brief_title>A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers ( REFLECTIONS B327-01 )</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Healthy male subject ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination include blood pressure pulse rate measurement , 12lead ECG , clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 total body weight &gt; 50 kg ( 110 lb ) . Male subject must agree female spouse/partners use adequate contraception ( 2 form birth control , one must barrier method ) nonchildbearing potential . Left ventricular ejection fraction ( LVEF ) within normal range measure echocardiogram ( ECHO ) within 8 week prior randomization . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic allergic disease , clinical finding screen exclude untreated , asymptomatic seasonal allergy time dose . Clinically significant abnormality laboratory test result . Previous exposure monoclonal antibody current use biologics . History allergic anaphylactic reaction therapeutic drug benzyl alcohol . Use prescription non prescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue 28 day prior first dose study medication . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity</keyword>
	<keyword>PK</keyword>
	<keyword>Phase I</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Healthy Male Volunteers</keyword>
	<keyword>Single-dose</keyword>
	<keyword>HER-2</keyword>
	<keyword>Oncology</keyword>
</DOC>